Simplifying Global Compliance
FDA Pushes Risk-Based Patient Selection for Microbial Vector Therapies
Clinical Trials Advisor
The FDA is calling for risk management plans for clinical development of microbial vectors for gene therapy, focusing on the potential for vectors to germinate, regerminate or reseed.
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing